相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
Andreas Hochhaus et al.
ANNALS OF HEMATOLOGY (2015)
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani et al.
ANNALS OF HEMATOLOGY (2015)
Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members
Alexander Deneka et al.
GENE (2015)
Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases
Elena Shagisultanova et al.
GENE (2015)
How I treat newly diagnosed chronic myeloid leukemia in 2015
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Better Therapeutic Trials in Ovarian Cancer
Michael A. Bookman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice
J. L. Little et al.
ONCOGENE (2014)
The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift
Clare J. Reade et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA (2014)
The role of the fallopian tube in the origin of ovarian cancer
Britt K. Erickson et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2013)
Targeted therapies and clinical trials in ovarian cancer
J. Dancey
ANNALS OF ONCOLOGY (2013)
Kinase CK2 Inhibition: An Update
G. Cozza et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Gene Expression Analyses Support Fallopian Tube Epithelium as the Cell of Origin of Epithelial Ovarian Cancer
Daniel J. O'Shannessy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
The Molecular Fingerprint of High Grade Serous Ovarian Cancer Reflects Its Fallopian Tube Origin
Mirjana Kessler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Expression of c-Src and phospho-Src in epithelial ovarian carcinoma
Yong-Wen Huang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Britta Stordal et al.
MOLECULAR ONCOLOGY (2013)
The changing landscape of therapeutic strategies for recurrent ovarian cancer
Klaus H. Baumann et al.
FUTURE ONCOLOGY (2012)
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Russell J. Schilder et al.
GYNECOLOGIC ONCOLOGY (2012)
CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Adam Siddiqui-Jain et al.
MOLECULAR CANCER THERAPEUTICS (2012)
An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer
Geetika Sethi et al.
PLOS ONE (2012)
Update of randomized trials in recurrent disease
E. Pujade-Lauraine et al.
ANNALS OF ONCOLOGY (2011)
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Src family kinases and paclitaxel sensitivity
Xiao-Feng Le et al.
CANCER BIOLOGY & THERAPY (2011)
Targeting Src in Mucinous Ovarian Carcinoma
Koji Matsuo et al.
CLINICAL CANCER RESEARCH (2011)
Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
Fabrice Pierre et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
Fabrice Pierre et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis
W. Glenn McCluggage
PATHOLOGY (2011)
Emergence of protein kinase CK2 as a key target in cancer therapy
Janeen H. Trembley et al.
BIOFACTORS (2010)
Enhanced Genetic Instability and Dasatinib Sensitivity in Mammary Tumor Cells Lacking NEDD9
Mahendra K. Singh et al.
CANCER RESEARCH (2010)
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
Adam Siddiqui-Jain et al.
CANCER RESEARCH (2010)
Targeted trials in ovarian cancer
Jonathan A. Ledermann et al.
GYNECOLOGIC ONCOLOGY (2010)
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
Igor Astsaturov et al.
SCIENCE SIGNALING (2010)
Src family kinases and receptors: Analysis of three activation mechanisms by dynamic systems modeling
Hendrik Fuss et al.
BIOPHYSICAL JOURNAL (2008)
Protein kinase CK2 in human diseases
Barbara Guerra et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Preclinical versus clinical drug combination studies
Ting-Chao Chou
LEUKEMIA & LYMPHOMA (2008)
Reverse transfection on cell arrays for high content screening microscopy
Holger Erfle et al.
NATURE PROTOCOLS (2007)
The role of Src in solid and hematologic malignancies - Development of new-generation Src inhibitors
Ricardo H. Alvarez et al.
CANCER (2006)
Analysis of cell-based RNAi screens
Michael Boutros et al.
GENOME BIOLOGY (2006)
Novel insights into c-Src
O Alper et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Casein kinase 2 (CK2)-mediated reduction of the activities of Src family tyrosine kinases in vitro
T Yokoyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2004)
The interplay between Src family kinases and receptor tyrosine kinases
PA Bromann et al.
ONCOGENE (2004)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37
Y Miyata et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Bioconductor: open software development for computational biology and bioinformatics
RC Gentleman et al.
GENOME BIOLOGY (2004)
Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity
A Donella-Deana et al.
BIOCHEMICAL JOURNAL (2003)
One-thousand-and-one substrates of protein kinase CK2?
F Meggio et al.
FASEB JOURNAL (2003)
Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers
JR Wiener et al.
GYNECOLOGIC ONCOLOGY (2003)
Src family kinases in tumor progression and metastasis
JM Summy et al.
CANCER AND METASTASIS REVIEWS (2003)
Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium
AST Wong et al.
GYNECOLOGIC ONCOLOGY (2001)
Role of Src expression and activation in human cancer
RB Irby et al.
ONCOGENE (2000)
Src family tyrosine kinases and growth factor signaling
CL Abram et al.
EXPERIMENTAL CELL RESEARCH (2000)
分享论文
